Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 28
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Monath, Thomas P. Gershman, Mark Erin Staples, J. and Barrett, Alan D.T. 2013. Vaccines.


    Nordin, James D. Parker, Emily D. Vazquez‐Benitez, Gabriela Kharbanda, Elyse O. Naleway, Allison Marcy, S. Michael Molitor, Beth Kuckler, Leslie and Baggs, James 2013. Safety of the Yellow Fever Vaccine: A Retrospective Study. Journal of Travel Medicine, Vol. 20, Issue. 6, p. 368.


    Rafferty, Ellen Duclos, Philippe Yactayo, Sergio and Schuster, Melanie 2013. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review. Vaccine, Vol. 31, Issue. 49, p. 5798.


    Ryman, Kate and Klimstra, William 2013. Viral Hemorrhagic Fevers.


    Thomas, Roger E. Spragins, Wendy and Lorenzetti, Diane L. 2013. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?. Vaccine, Vol. 31, Issue. 52, p. 6201.


    Matteelli, Alberto Carvalho, Anna Cristina C. and Bigoni, Sara 2012. Visiting Relatives and Friends (VFR), Pregnant, and Other Vulnerable Travelers. Infectious Disease Clinics of North America, Vol. 26, Issue. 3, p. 625.


    Barros, Maria CES Galasso, Tatiane GCM Chaib, Antônio JM Degallier, Nicolas Nagata, Tatsuya and Ribeiro, Bergmann M 2011. Yellow fever virus envelope protein expressed in insect cells is capable of syncytium formation in lepidopteran cells and could be used for immunodetection of YFV in human sera. Virology Journal, Vol. 8, Issue. 1, p. 261.


    Seligman, Stephen J. 2011. Yellow Fever Virus Vaccine–associated Deaths in Young Women1. Emerging Infectious Diseases, Vol. 17, Issue. 10, p. 1891.


    Thomas, Roger E. Lorenzetti, Diane L. Spragins, Wendy Jackson, Dave and Williamson, Tyler 2011. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine, Vol. 29, Issue. 28, p. 4544.


    Ferguson, Morag Shin, Jinho Knezevic, Ivana Minor, Philip and Barrett, Alan 2010. WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13–14 May 2009. Vaccine, Vol. 28, Issue. 52, p. 8236.


    Gardner, Christina L. and Ryman, Kate D. 2010. Yellow Fever: A Reemerging Threat. Clinics in Laboratory Medicine, Vol. 30, Issue. 1, p. 237.


    Martins, Reinaldo de Menezes Maia, Maria de Lourdes de S. Santos, Eliane Matos dos Cruz, Robson Leite de S. dos Santos, Paulo Roberto G. Carvalho, Sandra Maria Deotti Sato, Helena Keiko Schermann, Maria Teresa Mohrdieck, Renate Leal, Maria da Luz Fernandes and Homma, Akira 2010. Yellow Fever Vaccine Post-marketing Surveillance in Brazil. Procedia in Vaccinology, Vol. 2, Issue. 2, p. 178.


    Veras, Maria Amélia S.M. Flannery, Brendan de Moraes, José Cassio da Silva Teixeira, Antonia Maria and Luna, Expedito J.A. 2010. Yellow fever vaccination coverage among children in Brazilian capitals. Vaccine, Vol. 28, Issue. 39, p. 6478.


    Yaro, S. Zango, A. Rouamba, J. Diabaté, A. Dabiré, R. Kambiré, C. Tiendrebeogo, S. M. R. Yonli, T. Ouango, J. G. and Diagbouga, S. P. 2010. Situation épidémiologique de la fièvre jaune au Burkina Faso de 2003 à 2008. Bulletin de la Société de pathologie exotique, Vol. 103, Issue. 1, p. 44.


    Amanna, Ian J. and Slifka, Mark K. 2009. Wanted, dead or alive: New viral vaccines. Antiviral Research, Vol. 84, Issue. 2, p. 119.


    Domingo, Cristina and Niedrig, Matthias 2009. Safety of 17D derived yellow fever vaccines. Expert Opinion on Drug Safety, Vol. 8, Issue. 2, p. 211.


    Receveur, M.-C. Bruyand, M. Pistone, T. and Malvy, D. 2009. Vaccination antiamarile : mise au point à propos des effets indésirables rares et graves. Médecine et Maladies Infectieuses, Vol. 39, Issue. 4, p. 234.


    Whittembury, Alvaro Ramirez, Gladys Hernández, Herminio Ropero, Alba Maria Waterman, Steve Ticona, María Brinton, Margo Uchuya, Jorge Gershman, Mark Toledo, Washington Staples, Erin Campos, Clarense Martínez, Mario Chang, Gwong-Jen J. Cabezas, Cesar Lanciotti, Robert Zaki, Sherif Montgomery, Joel M. Monath, Thomas and Hayes, Edward 2009. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine, Vol. 27, Issue. 43, p. 5974.


    Brandler, Samantha and Tangy, Frédéric 2008. Recombinant vector derived from live attenuated measles virus: Potential for flavivirus vaccines. Comparative Immunology, Microbiology and Infectious Diseases, Vol. 31, Issue. 2-3, p. 271.


    Gaspar, Luciane P. Mendes, Ygara S. Yamamura, Anna M.Y. Almeida, Luiz F.C. Caride, Elena Gonçalves, Rafael B. Silva, Jerson L. Oliveira, Andréa C. Galler, Ricardo and Freire, Marcos S. 2008. Pressure-inactivated yellow fever 17DD virus: Implications for vaccine development. Journal of Virological Methods, Vol. 150, Issue. 1-2, p. 57.


    ×

Risk of fatal adverse events associated with 17DD yellow fever vaccine

  • C. J. STRUCHINER (a1), P. M. LUZ (a1), I. DOURADO (a2), H. K. SATO (a3), S. G. AGUIAR (a4), J. G. L. RIBEIRO (a5), R. C. R. SOARES (a6) and C. T. CODEÇO (a1)
  • DOI: http://dx.doi.org/10.1017/S0950268804002602
  • Published online: 01 November 2004
Abstract

Yellow fever (YF), an acute infectious disease, is endemic in the north and central-west of Brazil. This disease can be prevented by the use of a vaccine. In Brazil, four fatal adverse events have been associated with the YF vaccine used in the country (17DD vaccine). We briefly describe the last two fatalities, and estimate the risk of 17DD-associated fatal adverse events under different epidemiological scenarios. Controversies regarding the appropriate denominator that enters the estimation of risk serve as a motivation for each proposed scenario. The statistical procedures used show optimum behaviour when assessing the risk of rare events. Risk estimates vary from 0·043 (95% CI 0·017–0·110) to 2·131 (95% CI 0·109–12·071) fatalities per million doses administered. The robust estimates of the risk of fatal adverse events we present constitute an important element in future risk–benefit analysis and point to the need for good quality vaccine coverage and adverse-events surveillance data to assess the risk of vaccination. Although vaccination of YF endemic regions is necessary to maintain low disease prevalence, preventive administration of YF vaccine to the entire population should be cautiously analysed.

Copyright
Corresponding author
Dr C. J. Struchiner, Rua Benjamim Batista 22, 202, Jardim Botânico, CEP 22461-120, Rio de Janeiro, RJ, Brasil. (Email: stru@procc.fiocruz.br)
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×